Market Place
Sourcing Support
Aviceda Completes Phase 2b SIGLEC Study Enrollment for AVD-104
24 Sep 2024 //
BUSINESSWIRE
Aviceda Therapeutics Adds Erin Lavelle To Board Of Directors
10 Sep 2024 //
BUSINESSWIRE
Aviceda Announces Formation of Renowned European Clinical Advisory Board
08 Apr 2024 //
BUSINESSWIRE
Aviceda Announces First Patient Dosed in Part 2 of Trial Assessing AVD-104
01 Feb 2024 //
BUSINESSWIRE
Aviceda Announces Data from Part 1 of the Phase 2/3 SIGLEC Trial for AVD-104
16 Jan 2024 //
BUSINESSWIRE
Aviceda Announces First Patient Enrolled in Ph 2 GLYCO Trial Evaluating AVD-104
09 Jan 2024 //
BUSINESSWIRE
Aviceda Completes Enrollment in Part 1 of SIGLEC Phase 2/3 U.S. Clinical Trial
23 Oct 2023 //
BUSINESSWIRE
Aviceda Announces AVD-104, Novel Glycomimetic Nanoparticle, Demonstrates Safety
11 Oct 2023 //
BUSINESSWIRE
Aviceda To Present at Major European Healthcare Conferences Highlighting AVD-104
25 Sep 2023 //
BUSINESSWIRE
Aviceda Announces Presentations on AVD-104, a Novel Glyco-Mimetic Nanoparticle
19 Jul 2023 //
BUSINESSWIRE
Aviceda Announces Dosing of First Patient With AVD-104
01 Jun 2023 //
BUSINESSWIRE
Aviceda Therapeutics Appoints Biopharma and Business Senior Executive
16 May 2023 //
BUSINESSWIRE
Aviceda Announces FDA Clearance of the IND Application for AVD-104
13 Apr 2023 //
BUSINESSWIRE
Aviceda Announces Strategic Partnership with Queen’s University Belfast (QUB)
10 Apr 2023 //
BUSINESSWIRE
Aviceda Announces 3 Presentations about AVD-104
03 Apr 2023 //
BUSINESSWIRE
Aviceda Announces Successful Submission of an IND & FTD Application for AVD-104
20 Mar 2023 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.